Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?

H Valerie Curran, Chandni Hindocha, Celia J A Morgan, Natacha Shaban, Ravi K Das, Tom P Freeman

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BACKGROUND: Changes in cannabis regulation globally make it increasingly important to determine what predicts an individual's risk of experiencing adverse drug effects. Relevant studies have used diverse self-report measures of cannabis use, and few include multiple biological measures. Here we aimed to determine which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like symptoms.

METHOD: In a naturalistic study, 410 young cannabis users were assessed once when intoxicated with their own cannabis and once when drug-free in counterbalanced order. Biological measures of cannabinoids [(Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN) and their metabolites)] were derived from three samples: each participant's own cannabis (THC, CBD), a sample of their hair (THC, THC-OH, THC-COOH, CBN, CBD) and their urine (THC-COOH/creatinine). Comprehensive self-report measures were also obtained. Self-reported and clinician-rated assessments were taken for cannabis dependency [Severity of Dependence Scale (SDS), DSM-IV-TR] and acute psychotic-like symptoms [Psychotomimetic State Inventory (PSI) and Brief Psychiatric Rating Scale (BPRS)].

RESULTS: Cannabis dependency was positively associated with days per month of cannabis use on both measures, and with urinary THC-COOH/creatinine for the SDS. Acute psychotic-like symptoms were positively associated with age of first cannabis use and negatively with urinary THC-COOH/creatinine; no predictors emerged for BPRS.

CONCLUSIONS: Levels of THC exposure are positively associated with both cannabis dependency and tolerance to the acute psychotic-like effects of cannabis. Combining urinary and self-report assessments (use frequency; age first used) enhances the measurement of cannabis use and its association with adverse outcomes.

Original languageEnglish
Pages (from-to)1574-1580
Number of pages7
JournalPsychological Medicine
Volume49
Issue number9
Early online date4 Sep 2018
DOIs
Publication statusPublished - 1 Jul 2019

Fingerprint

Cannabis
Self Report
Dronabinol
Cannabidiol
Cannabinol
Brief Psychiatric Rating Scale
Creatinine
Dependency (Psychology)
Cannabinoids
Diagnostic and Statistical Manual of Mental Disorders
Pharmaceutical Preparations

Keywords

  • Biological markers
  • cannabinoids
  • cannabis
  • predictors of dependence
  • predictors of psychotic-like
  • self-report measures

ASJC Scopus subject areas

  • Applied Psychology
  • Psychiatry and Mental health

Cite this

Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects? / Curran, H Valerie; Hindocha, Chandni; Morgan, Celia J A; Shaban, Natacha; Das, Ravi K; Freeman, Tom P.

In: Psychological Medicine, Vol. 49, No. 9, 01.07.2019, p. 1574-1580.

Research output: Contribution to journalArticle

Curran, H Valerie ; Hindocha, Chandni ; Morgan, Celia J A ; Shaban, Natacha ; Das, Ravi K ; Freeman, Tom P. / Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?. In: Psychological Medicine. 2019 ; Vol. 49, No. 9. pp. 1574-1580.
@article{7a5e8c2228914239b901b6621f33dc89,
title = "Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?",
abstract = "BACKGROUND: Changes in cannabis regulation globally make it increasingly important to determine what predicts an individual's risk of experiencing adverse drug effects. Relevant studies have used diverse self-report measures of cannabis use, and few include multiple biological measures. Here we aimed to determine which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like symptoms.METHOD: In a naturalistic study, 410 young cannabis users were assessed once when intoxicated with their own cannabis and once when drug-free in counterbalanced order. Biological measures of cannabinoids [(Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN) and their metabolites)] were derived from three samples: each participant's own cannabis (THC, CBD), a sample of their hair (THC, THC-OH, THC-COOH, CBN, CBD) and their urine (THC-COOH/creatinine). Comprehensive self-report measures were also obtained. Self-reported and clinician-rated assessments were taken for cannabis dependency [Severity of Dependence Scale (SDS), DSM-IV-TR] and acute psychotic-like symptoms [Psychotomimetic State Inventory (PSI) and Brief Psychiatric Rating Scale (BPRS)].RESULTS: Cannabis dependency was positively associated with days per month of cannabis use on both measures, and with urinary THC-COOH/creatinine for the SDS. Acute psychotic-like symptoms were positively associated with age of first cannabis use and negatively with urinary THC-COOH/creatinine; no predictors emerged for BPRS.CONCLUSIONS: Levels of THC exposure are positively associated with both cannabis dependency and tolerance to the acute psychotic-like effects of cannabis. Combining urinary and self-report assessments (use frequency; age first used) enhances the measurement of cannabis use and its association with adverse outcomes.",
keywords = "Biological markers, cannabinoids, cannabis, predictors of dependence, predictors of psychotic-like, self-report measures",
author = "Curran, {H Valerie} and Chandni Hindocha and Morgan, {Celia J A} and Natacha Shaban and Das, {Ravi K} and Freeman, {Tom P}",
year = "2019",
month = "7",
day = "1",
doi = "10.1017/S003329171800226X",
language = "English",
volume = "49",
pages = "1574--1580",
journal = "Psychological Medicine",
issn = "1469-8978",
publisher = "Cambridge University Press",
number = "9",

}

TY - JOUR

T1 - Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?

AU - Curran, H Valerie

AU - Hindocha, Chandni

AU - Morgan, Celia J A

AU - Shaban, Natacha

AU - Das, Ravi K

AU - Freeman, Tom P

PY - 2019/7/1

Y1 - 2019/7/1

N2 - BACKGROUND: Changes in cannabis regulation globally make it increasingly important to determine what predicts an individual's risk of experiencing adverse drug effects. Relevant studies have used diverse self-report measures of cannabis use, and few include multiple biological measures. Here we aimed to determine which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like symptoms.METHOD: In a naturalistic study, 410 young cannabis users were assessed once when intoxicated with their own cannabis and once when drug-free in counterbalanced order. Biological measures of cannabinoids [(Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN) and their metabolites)] were derived from three samples: each participant's own cannabis (THC, CBD), a sample of their hair (THC, THC-OH, THC-COOH, CBN, CBD) and their urine (THC-COOH/creatinine). Comprehensive self-report measures were also obtained. Self-reported and clinician-rated assessments were taken for cannabis dependency [Severity of Dependence Scale (SDS), DSM-IV-TR] and acute psychotic-like symptoms [Psychotomimetic State Inventory (PSI) and Brief Psychiatric Rating Scale (BPRS)].RESULTS: Cannabis dependency was positively associated with days per month of cannabis use on both measures, and with urinary THC-COOH/creatinine for the SDS. Acute psychotic-like symptoms were positively associated with age of first cannabis use and negatively with urinary THC-COOH/creatinine; no predictors emerged for BPRS.CONCLUSIONS: Levels of THC exposure are positively associated with both cannabis dependency and tolerance to the acute psychotic-like effects of cannabis. Combining urinary and self-report assessments (use frequency; age first used) enhances the measurement of cannabis use and its association with adverse outcomes.

AB - BACKGROUND: Changes in cannabis regulation globally make it increasingly important to determine what predicts an individual's risk of experiencing adverse drug effects. Relevant studies have used diverse self-report measures of cannabis use, and few include multiple biological measures. Here we aimed to determine which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like symptoms.METHOD: In a naturalistic study, 410 young cannabis users were assessed once when intoxicated with their own cannabis and once when drug-free in counterbalanced order. Biological measures of cannabinoids [(Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN) and their metabolites)] were derived from three samples: each participant's own cannabis (THC, CBD), a sample of their hair (THC, THC-OH, THC-COOH, CBN, CBD) and their urine (THC-COOH/creatinine). Comprehensive self-report measures were also obtained. Self-reported and clinician-rated assessments were taken for cannabis dependency [Severity of Dependence Scale (SDS), DSM-IV-TR] and acute psychotic-like symptoms [Psychotomimetic State Inventory (PSI) and Brief Psychiatric Rating Scale (BPRS)].RESULTS: Cannabis dependency was positively associated with days per month of cannabis use on both measures, and with urinary THC-COOH/creatinine for the SDS. Acute psychotic-like symptoms were positively associated with age of first cannabis use and negatively with urinary THC-COOH/creatinine; no predictors emerged for BPRS.CONCLUSIONS: Levels of THC exposure are positively associated with both cannabis dependency and tolerance to the acute psychotic-like effects of cannabis. Combining urinary and self-report assessments (use frequency; age first used) enhances the measurement of cannabis use and its association with adverse outcomes.

KW - Biological markers

KW - cannabinoids

KW - cannabis

KW - predictors of dependence

KW - predictors of psychotic-like

KW - self-report measures

UR - http://www.scopus.com/inward/record.url?scp=85052929061&partnerID=8YFLogxK

U2 - 10.1017/S003329171800226X

DO - 10.1017/S003329171800226X

M3 - Article

VL - 49

SP - 1574

EP - 1580

JO - Psychological Medicine

JF - Psychological Medicine

SN - 1469-8978

IS - 9

ER -